174 related articles for article (PubMed ID: 30519357)
41. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
[TBL] [Abstract][Full Text] [Related]
42. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
Wang S; Li S; Shen L
Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
[TBL] [Abstract][Full Text] [Related]
43. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
[TBL] [Abstract][Full Text] [Related]
44. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
[TBL] [Abstract][Full Text] [Related]
45. The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials.
Sheng J; Yang YP; Zhao YY; Qin T; Hu ZH; Zhou T; Zhang YX; Hong SD; Ma YX; Zhao HY; Huang Y; Zhang L
Medicine (Baltimore); 2015 Aug; 94(34):e1400. PubMed ID: 26313787
[TBL] [Abstract][Full Text] [Related]
46. [Anti-EGFR monoclonal antibodies in recurrent and/or metastatic head and neck squamous cell carcinoma: a meta-analysis].
Song Q; Li X; Li B; Di B; Xiao S
Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(22):1779-83. PubMed ID: 26704167
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.
Hong X; Wang G; Xu G; Shi W; Wang T; Rong Z; Mo C
Medicine (Baltimore); 2022 Jan; 101(3):e28507. PubMed ID: 35060503
[TBL] [Abstract][Full Text] [Related]
48. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
49. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis.
Shen J; Sun C; Zhou M; Zhang Z
Onco Targets Ther; 2019; 12():2477-2494. PubMed ID: 31040691
[TBL] [Abstract][Full Text] [Related]
50. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
[TBL] [Abstract][Full Text] [Related]
51. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
52. Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Xue Y; Li G; Xie T; Xu H; Xu T; Li Z; Zhu L; Li X; Li Z; Xiong W
Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3097-3106. PubMed ID: 37079074
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of concurrent chemoradiotherapy with induction chemotherapy
Liu Y; Yang L; Zhang S; Lin B
Transl Cancer Res; 2022 May; 11(5):1207-1218. PubMed ID: 35706809
[TBL] [Abstract][Full Text] [Related]
54. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
Xia WX; Liang H; Lv X; Wang L; Qian CN; Ye YF; Ke LR; Qiu WZ; Yu YH; Huang XJ; Liu GY; Zhao C; Xiang YQ; Guo X
Oral Oncol; 2017 Apr; 67():167-174. PubMed ID: 28351572
[TBL] [Abstract][Full Text] [Related]
55. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
56. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
57. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
58. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
Wang L; Zhuang H; Xu X; Zhou J; Jiao Y
Front Oncol; 2023; 13():1129649. PubMed ID: 36814816
[TBL] [Abstract][Full Text] [Related]
60. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
